



EUROPEAN RESPIRATORY *journal*

FLAGSHIP SCIENTIFIC JOURNAL OF ERS



CFTR mutations unidentified in CFTR2 database and their phenotypic characteristics: Data from cystic fibrosis registry of Turkey

Güzin Cinel, Deniz Doğru, Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Nazan Çobanoğlu, Sevgi Pekcan, Ebru Yalçın, Nural Kiper, Velat Şen, Hadice Selimoğlu Şen, Ömür Ercan, Özlem Keskin, Sevgi Bilgiç Eltan, Lina Muhammed Al Shadfan, Hakan Yazan, Derya Ufuk Altıntaş, Şenay Şaşıhüseyinoğlu, Nihat Sapan, Şükrü Çekiç, Haluk Çokuğraş, Ayşe Ayzıt Atabek, Tuğba Ramaslı Gürsoy, Ayşe Tana Aslan, Ayşen Bingöl, Abdurrahman Erdem Başaran, Ali Özdemir, Mehmet Köse, Melih Hangül, Nagehan Emiralioğlu, Gökçen Tuğcu, Hasan Yüksel, Özge Yılmaz, Fazıl Orhan, Zeynep Gökçe Gayretli aydın, Erdem Topal, Zeynep Tamay, Ayşe Süleyman, Demet Can, Cem Murat Bal, Gönül Çaltepe, Uğur Özçelik

European Respiratory Journal 2020 56: 2765; DOI: 10.1183/13993003.congress-2020.2765

Article

Info & Metrics

Abstract

Background: Cystic Fibrosis Registry of Turkey shows various CFTR mutations due to the geographical location and historical background of our country, and also high prevalence of consanguineous marriages.

Method:All mutations detected in the Cystic Fibrosis Registry of Turkey 2017 (CFRT2017) data were screened in CFTR1 and CFTR2 databases. Mutations which were not found in both were identified and characteristics of these patients were compared with F508del homozygous patients.

Results: Among 1170 registered patients, 978 were genotyped and 200 different mutations were shown in 1270 alleles. 29 mutations were not reported in both databases; 58 mutations have been reported in CFTR1 but not in CFTR2. Demographic and phenotypic characteristics of the 112 patients with 87 different alleles those were not previously reported in the CFTR2 database (nonCFTR2 group) were compared with F508del homozygous 103 patients in CFRT2017. In the nonCFTR2 group, mean age was younger (5.81 vs 7.69; p:0.015), mean age at

THANK YOU FOR ACCEPTING COOKIES

You can now hide this message or find out more about cookies.

Hide

More info

Conclusion: We suggest that patients in the nonCFTR2 group have a mild clinical course, but in some patients, further investigations and functional studies are required for the exact diagnosis.

[Children](#) [Cystic fibrosis](#) [Genetics](#)

Footnotes

Cite this article as: *European Respiratory Journal* 2020; 56: Suppl. 64, 2765.

This abstract was presented at the 2020 ERS International Congress, in session "Respiratory viruses in the "pre COVID-19" era".

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

Copyright ©the authors 2020

We recommend

First identified "severe" mutations and extended rearrangements in the CFTR gene in Russian cystic fibrosis patients

Elena Kondratyeva et al., *European Respiratory Journal*, 2020

Description of new CFTR gene's mutations in patients of Russia

Yulia Gorinova et al., *European Respiratory Journal*

Clinical presentation in CF patients with large deletions

Guergana Petrova et al., *European Respiratory Journal*

Cystic Fibrosis Patients Eligible for Modulator Drugs: Data from Cystic Fibrosis Registry of Turkey

Fatma Nazan Çobanoğlu et al., *European Respiratory Journal*, 2019

A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
Koliarne Tong et al., *European Respiratory Journal*, 2019

Biological characterization of F508delCFTR protein processing by the CFTR Corrector ABBV-2222/GLPG2222

Ashvani K Singh et al., *J Pharmacol Exp Ther*, 2019

ORKAMBI®-mediated rescue of mucociliary clearance in CF primary respiratory cultures is enhanced by arginine uptake, arginase inhibition and promotion of nitric oxide signaling to the CFTR channel

Yu-Sheng Wu et al., *Mol Pharmacol*, 2019

Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del

Stephanie Chin et al., *Mol Pharmacol*, 2018

FDA Identifies a list of 223 Most Needed Meds to Address Urgent Medical Conditions

MRP, 2020

Probiotics may be considered for children and adults with cystic fibrosis

James Hill et al., *Evid Based Nurs*, 2020

THANK YOU FOR ACCEPTING COOKIES

You can now hide this message or find out more about cookies.

Hide

More info